MX339374B - Cocristales ionicos con base en metformina. - Google Patents

Cocristales ionicos con base en metformina.

Info

Publication number
MX339374B
MX339374B MX2011004549A MX2011004549A MX339374B MX 339374 B MX339374 B MX 339374B MX 2011004549 A MX2011004549 A MX 2011004549A MX 2011004549 A MX2011004549 A MX 2011004549A MX 339374 B MX339374 B MX 339374B
Authority
MX
Mexico
Prior art keywords
contra
ionic
crystals
active principles
tablets
Prior art date
Application number
MX2011004549A
Other languages
English (en)
Other versions
MX2011004549A (es
Inventor
Jose Manuel Francisco Lara Ochoa
Original Assignee
Inst De Investigación En Química Aplic S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Investigación En Química Aplic S A De C V filed Critical Inst De Investigación En Química Aplic S A De C V
Priority to MX2011004549A priority Critical patent/MX339374B/es
Priority to PCT/MX2012/000043 priority patent/WO2012148252A2/es
Publication of MX2011004549A publication Critical patent/MX2011004549A/es
Publication of MX339374B publication Critical patent/MX339374B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se ha inventado dos nuevos compuestos con base en metformina usando como contraiones, en un caso el antidiabético glimepirida y en el otro caso el antidiabético de primer nivel pioglitazona. La espectroscopia obtenida así como el estudio de sus propiedades fisicoquímicas indican que en el estado sólido ambos compuestos corresponden con cocristales iónicos atraídos por fuerzas iónicas e interacciones de tipo puente de hidrógeno. Las propiedades fisicoquímicas de los cocristales iónicos muestran que poseen mayores velocidades de disolución intrínseca y mejores solubilidades que la de los contraiones precursores, propiedades que pueden impactar favorablemente la biodisponibilidad de los nuevos principios activos. Estos nuevos principios activos mejorados se formularon en composiciones farmacéuticas de sólidos orales como tabletas o capletas que presentan ventajas sobre las tabletas comerciales existentes. Con estas bases, las tabletas conteniendo los nuevos principios activos representan un tratamiento mejorado para el control de la glucosa en sangre en pacientes con diabetes tipo II.
MX2011004549A 2011-04-29 2011-04-29 Cocristales ionicos con base en metformina. MX339374B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2011004549A MX339374B (es) 2011-04-29 2011-04-29 Cocristales ionicos con base en metformina.
PCT/MX2012/000043 WO2012148252A2 (es) 2011-04-29 2012-04-20 Cocristales ionicos con base en metformina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011004549A MX339374B (es) 2011-04-29 2011-04-29 Cocristales ionicos con base en metformina.

Publications (2)

Publication Number Publication Date
MX2011004549A MX2011004549A (es) 2013-01-10
MX339374B true MX339374B (es) 2016-05-13

Family

ID=47072969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004549A MX339374B (es) 2011-04-29 2011-04-29 Cocristales ionicos con base en metformina.

Country Status (2)

Country Link
MX (1) MX339374B (es)
WO (1) WO2012148252A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022050832A1 (es) 2020-09-02 2022-03-10 Laboratorios Silanes S.A. De C.V. Medicamento de combinación para el control y manejo de la diabetes mellitus tipo 2

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9815777B2 (en) * 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CN108299271A (zh) * 2018-01-29 2018-07-20 重庆医科大学 一种加合物及其制备和用途
CN110357871A (zh) * 2019-07-03 2019-10-22 天津大学 二甲双胍-吡格列酮盐及其制备方法和应用
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482919B1 (en) * 2002-01-25 2007-05-02 Laboratorios Silanes, S.A. de C.V. Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
CN101531657B (zh) * 2009-04-23 2013-10-16 重庆医科大学 噻唑烷二酮类药物的二甲双胍盐及其制备方法和用途
WO2011128782A2 (en) * 2010-04-13 2011-10-20 Jorge Luis Rosado Compositions and methods for treating type ii diabetes and related disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022050832A1 (es) 2020-09-02 2022-03-10 Laboratorios Silanes S.A. De C.V. Medicamento de combinación para el control y manejo de la diabetes mellitus tipo 2

Also Published As

Publication number Publication date
WO2012148252A3 (es) 2012-12-20
MX2011004549A (es) 2013-01-10
WO2012148252A2 (es) 2012-11-01

Similar Documents

Publication Publication Date Title
MX339374B (es) Cocristales ionicos con base en metformina.
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
MX342423B (es) Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
MX2008012017A (es) Pirazoles como inhibidores de 11-beta-hsd1.
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
EA026385B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
NO20074872L (no) Pyrazoler
WO2011056985A3 (en) Substituted heterocyclic compounds
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
WO2012117000A8 (en) 3-amino-pyridines as gpbar1 agonists
MX2012013465A (es) Lactamas sustituidas con piperidinilo como moduladores de gpr119.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
JO2515B1 (en) Gamma crystalline form of epabradine hydrochloride, its preparation process and its pharmaceutical ingredients
MY151295A (en) Pyrimidyl indoline compound
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2011006935A3 (en) Tetrazole derivatives
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.

Legal Events

Date Code Title Description
FG Grant or registration